Racura Oncology

Targetted cancer therapy
#Interview #Oncology #Precision medicine #Racura Oncology

Why G‑quadruplex biology is back and what it means for MYC‑driven cancers

Racura Oncology recently raised AU$34.3 (US$24.31) million to fund its RC220 clinical programmes in acute myeloid leukaemia (AML), epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer, and anthracycline cardioprotection in solid tumour patients.  Diana Turner speaks to Dr Peter Smith, Executive Chair of Racura, about the company’s approach… Read More

#Cancer Research #Exclusive Content